Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2018-03-15 Regulatory Filings
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 14, 2018. It includes an announcement of the company's financial results for the quarter ended December 31, 2017, but the actual financial results are provided in an attached press release (Exhibit 99.1). The 8-K itself does not contain detailed financial statements or substantive financial data, only a summary and reference to the press release. Additionally, the document announces a management change (appointment of a new Senior Vice President and CFO). Since the document is primarily an announcement of events (financial results release and management appointment) rather than the full financial report, and given the presence of management change information, the best classification is a Regulatory Filing (RNS) because it does not contain the full financial report or detailed management discussion but announces these events. The document length is about 5,419 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is RNS with high confidence.
2018-03-15 English
FORM 10-K
Annual Report FY 2017
2018-03-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-09 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-08 English
FORM 4 SUBMISSION
Director's Dealing
2018-02-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.